HomeCompareABSCF vs VICI

ABSCF vs VICI: Dividend Comparison 2026

ABSCF yields 137.93% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABSCF wins by $15.49M in total portfolio value
10 years
ABSCF
ABSCF
● Live price
137.93%
Share price
$1.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.45M
Annual income
$6,780,916.45
Full ABSCF calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — ABSCF vs VICI

📍 ABSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABSCFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABSCF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABSCF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABSCF
Annual income on $10K today (after 15% tax)
$11,724.14/yr
After 10yr DRIP, annual income (after tax)
$5,763,778.98/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, ABSCF beats the other by $5,247,509.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABSCF + VICI for your $10,000?

ABSCF: 50%VICI: 50%
100% VICI50/50100% ABSCF
Portfolio after 10yr
$8.71M
Annual income
$3,694,146.28/yr
Blended yield
42.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ABSCF
No analyst data
Altman Z
-1.3
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABSCF buys
0
VICI buys
0
No recent congressional trades found for ABSCF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABSCFVICI
Forward yield137.93%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$16.45M$966.2K
Annual income after 10y$6,780,916.45$607,376.13
Total dividends collected$15.13M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ABSCF vs VICI ($10,000, DRIP)

YearABSCF PortfolioABSCF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$24,493$13,793.10$11,361$941.49+$13.1KABSCF
2$57,781$31,573.45$13,320$1,481.32+$44.5KABSCF
3$131,437$69,611.34$16,284$2,405.01+$115.2KABSCF
4$288,626$147,988.71$21,040$4,071.78+$267.6KABSCF
5$612,543$303,712.69$29,209$7,285.49+$583.3KABSCF
6$1,257,814$602,392.61$44,443$14,006.51+$1.21MABSCF
7$2,501,908$1,156,047.28$75,822$29,512.55+$2.43MABSCF
8$4,826,093$2,149,051.62$148,733$69,726.75+$4.68MABSCF
9$9,038,168$3,874,248.32$344,394$189,413.75+$8.69MABSCF
10$16,451,756$6,780,916.45$966,234$607,376.13+$15.49MABSCF

ABSCF vs VICI: Complete Analysis 2026

ABSCFStock

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Full ABSCF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this ABSCF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABSCF vs SCHDABSCF vs JEPIABSCF vs OABSCF vs KOABSCF vs MAINABSCF vs NNNABSCF vs EPRTABSCF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.